Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 2Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal 1Carcinoma, Hepatocellular 1Advanced Pancreatic Cancer 1Advanced Gastric Cancer 1Advanced Colorectal Cancer 1

Interventions

apatinib 9Paclitaxel 9Capecitabine 7Oxaliplatin 6camrelizumab 5Cisplatin 5S 1 (combination) 4Fluorouracil 3Docetaxel 3130-nm albumin-bound paclitaxel 3titanium silicide 2Leucovorin 2Drug Therapy 2vorolanib 1trifluridine tipiracil drug combination 1tipiracil 1spartalizumab 1rucaparib 1relatlimab 1raltitrexed 1pazopanib 1olaparib 1lobaplatin 1linrodostat 1ezogabine 1endostar protein 1durvalumab 1dacomitinib 1capivasertib 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastric Cancer × endostar protein × Gastrointestinal × Clear all
NCT00842491 2015-05-19

Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer

Peking University

Phase 2 Completed
45 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡